flurbiprofen + rifampicin

Flurbiprofen + rifampicin is a combination of two small molecule drugs, each with distinct mechanisms and clinical uses. Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) that acts primarily by inhibiting cyclooxygenase-1 and -2 (COX-1/COX-2), leading to decreased prostaglandin synthesis, which results in analgesic, anti-inflammatory, and antipyretic effects[3][7]. Rifampicin (also known as rifampin) is an antibiotic that inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing RNA synthesis and bacterial replication; it is mainly used for the treatment of tuberculosis and to eliminate Neisseria meningitidis from the nasopharynx[2][6]. There are no widely recognized fixed-dose combination products or unique brand names for this specific pairing. The co-administration of these drugs may be considered in rare clinical scenarios but carries significant risk for drug-drug interactions—rifampicin induces hepatic enzymes that can increase the metabolism of flurbiprofen, potentially reducing its efficacy while increasing hepatotoxicity risk when both are used together[1][3][5].